ACTRN12619000179134已完成未知
A prospective, non-randomized, multi-center, open-label clinical investigation to assess the safety and technical performance of the Emboliner embolic protection catheter.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 31
研究概览
简要总结
- Research Question The primary purpose of the SafePass 2 evaluation was to evaluate the safety and technical feasibility of the Emboliner™ embolic protection catheter. 2. Background Information SafePass 2 was a safety and feasibility study of the Generation 2 Emboliner™ during Transcatheter Aortic Valve Replacement (TAVR). Cerebral embolism is a known complication of cardiac surgery. Embolic particles, which may include thrombi, valvular tissue, and foreign material, may become dislodged by surgical or catheter manipulations and enter the bloodstream which can lead to neurological and neurocognitive deficits, stroke, or death. The Emboliner™ embolic protection catheter provides embolic protection during interventional cardiology procedures, such as transcatheter aortic valve replacement (TAVR). 3. Participant Characteristics Thirty-one (31) patients with severe aortic stenosis were enrolled. Subjects enrolled ranged in age from 65 to 92, with an average age of 79. 4. Key Results Thirty-one (31) subjects were enrolled into the SafePass 2 study at three (3) sites in New Zealand, from April 2019 to November 2019. Two (2) of the thirty-one (31) subjects (6%) experienced a MACCE (defined as: death, stroke, or Stage 3 acute kidney injury). Both events had no causal relationship to the Emboliner™ system, as determined by the Investigator. Of the thirty-one (31) subjects, full technical success was met in all cases (100%). The Emboliner™ is technically feasible for use.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.The patient must be 18 years and older
- •2.The patient must be a candidate for TAVR according
- •3.The patient has been provided written informed consent
排除标准
- •1.Patients with an ascending aortic diameter [that meets the requirements of product labeling]
- •2.Patients with the linear distance from the femoral access site to the aortic valve root [per product labeling]
- •3.Patients not undergoing TAVR via the trans-femoral route.
- •4.Patients that are contraindicated for anticoagulant and/or antiplatelet therapy or uncorrected bleeding disorder.
- •5. Pregnant or nursing subjects, or subjects who intend to become pregnant during the term of the study.
- •6. Patients with known diagnosis of acute myocardial infarction (AMI) within 30 days preceding the index procedure.
- •7. Patients with known other mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation, or is associated with a life expectancy of less than one year.
- •8. Patients with severe allergy to study materials or required medication that cannot be adequately pre-medicated or adequately controlled.
- •9. Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months.
- •10. Patients with an active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 months.
- •11. Patients with renal failure.
- •12. Patients presenting with cardiogenic shock or severe hypotension.
- •13. Patients with severe peripheral arterial disease that precludes delivery sheath vascular access, or whose vascular anatomy is unable to accommodate the access sheath.
- •14. Patients who have a planned treatment with any other investigational device or procedure during the study period.
- •15. Patients planned to undergo any other cardiac surgical or interventional procedure within two (2) weeks prior to the TAVR procedure, or 30 days after the TAVR procedure.
- •16. Patients with aortic implant or other abnormality (e.g., asymmetrical or sharp aortic calcifications).
- •17. Emergency patients.
研究者
相似试验
终止
2 期
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerBiliary Tract CancerNCT05998447Genome & Company10
进行中（未招募）
2 期
A multi center, phase 2 study to Evaluate safety and efficacy of total Neoadjuvant treatment of long courSE radiotherapy followed by cheMotherapy, capecitaBine combined with oxaliplatin (CAPOX) for Locally advanced rEctal cancer(ENSEMBLE-2)JPRN-jRCTs071210143KAGAWA Yoshinori27
招募中
1 期
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLLarge B-cell LymphomaNCT06375733Genfleet Therapeutics (Shanghai) Inc.51
进行中（未招募）
2 期
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Gastric Cancer Stage IIINCT04515615Yu jiren52
进行中（未招募）
不适用
A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-targeted therapiesEUCTR2009-017871-13-PLew Medical Enzymes AG